Constantinos Zambirinis, MD, MRes, FSSO
@czambir.bsky.social
Surgical Oncologist & Docent at Linköping University.
🔬Studying #PancreaticCancer #Metastasis #Immunology
🔬Studying #PancreaticCancer #Metastasis #Immunology
Just found my new favorite trial: the DECAF trial!!!
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation url: jamanetwork.com/journals/jam...
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation url: jamanetwork.com/journals/jam...
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation
This clinical trial compares the effect of caffeinated coffee consumption vs abstinence from coffee and caffeine on recurrent atrial fibrillation.
jamanetwork.com
November 10, 2025 at 6:15 PM
Just found my new favorite trial: the DECAF trial!!!
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation url: jamanetwork.com/journals/jam...
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation url: jamanetwork.com/journals/jam...
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
Metformin, the first line drug for Type 2 diabetes, has been used for 60 years without a clearcut mechanism of action. It turns out it's not just reducing glucose output from the liver. Metformin also works via the brain www.science.org/doi/10.1126/...
Low-dose metformin requires brain Rap1 for its antidiabetic action
Metformin lowers blood glucose by inhibiting Rap1 in ventromedial hypothalamic neurons that regulate glucose balance.
www.science.org
July 31, 2025 at 6:52 PM
Metformin, the first line drug for Type 2 diabetes, has been used for 60 years without a clearcut mechanism of action. It turns out it's not just reducing glucose output from the liver. Metformin also works via the brain www.science.org/doi/10.1126/...
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
Multi-omic underpinnings of Alzheimer's disease promote inflammation (particularly via T cells)whereas those for stroke relate to vascular integrity @cp-neuron.bsky.social
www.cell.com/neuron/abstr...
www.cell.com/neuron/abstr...
Human brain vascular multi-omics elucidates disease-risk associations
Reid et al. develop MultiVINE-seq to map thousands of non-coding disease variants
to genes in human brain vascular cells. Cerebrovascular disease variants compromise
vessel integrity, whereas Alzheime...
www.cell.com
July 28, 2025 at 3:04 PM
Multi-omic underpinnings of Alzheimer's disease promote inflammation (particularly via T cells)whereas those for stroke relate to vascular integrity @cp-neuron.bsky.social
www.cell.com/neuron/abstr...
www.cell.com/neuron/abstr...
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
NEW content online!
Endoplasmic reticulum stress responses in anticancer immunity
Nature Reviews Cancer, Published online: 24 June 2025; doi:10.1038/s41568-025-00836-5The endoplasmic reticulum (ER) has a central role in mounting effective and durable antitumour immunity. In this Review, Hwang et al. outline how tumour-induced ER stress responses alter the function of intratumoural immune cells and the efficacy of immunotherapy, highlighting the potential of unfolded protein response-targeted interventions to improve cancer outcomes.
www.nature.com
June 24, 2025 at 1:45 PM
NEW content online!
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread: @cp-cancercell.bsky.social www.cell.com/cancer-cell/...
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread
Garner et al. demonstrate that mammary tumors skew hematopoiesis toward myeloid development.
Tumor-induced immunosuppressive programming of neutrophils begins early in hematopoiesis
and progressively ...
www.cell.com
May 12, 2025 at 9:58 PM
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread: @cp-cancercell.bsky.social www.cell.com/cancer-cell/...
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
Interesting preprint on TCR-pMHC prediction and functional validation, with a great thread! 👇🏼
By the Shumacher Lab
By the Shumacher Lab
It's not the models, it's the data!
We show that a substantial proportion of a widely used TCR-pMHC database does not functionally validate, causing underestimation of performance of TCR-pMHC prediction models.
www.biorxiv.org/content/10.1...
We show that a substantial proportion of a widely used TCR-pMHC database does not functionally validate, causing underestimation of performance of TCR-pMHC prediction models.
www.biorxiv.org/content/10.1...
A functionally validated TCR-pMHC database for TCR specificity model development
Accurate prediction of TCR specificity forms a holy grail in immunology and large language models and computational structure predictions provide a path to achieve this. Importantly, current TCR-pMHC ...
www.biorxiv.org
May 5, 2025 at 6:11 AM
Interesting preprint on TCR-pMHC prediction and functional validation, with a great thread! 👇🏼
By the Shumacher Lab
By the Shumacher Lab
Risk of Colorectal Cancer Associated With Frequency of Colorectal Polyp Diagnosis in Relatives - @gastroenterology.bsky.social www.gastrojournal.org/article/S001...
April 21, 2025 at 3:07 PM
Risk of Colorectal Cancer Associated With Frequency of Colorectal Polyp Diagnosis in Relatives - @gastroenterology.bsky.social www.gastrojournal.org/article/S001...
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
The US National Institutes of Health has terminated nearly 800 research projects at a breakneck pace, wiping out significant chunks of funding to entire scientific fields
Read the full story: https://go.nature.com/3EuFRPV
Read the full story: https://go.nature.com/3EuFRPV
April 18, 2025 at 10:19 AM
The US National Institutes of Health has terminated nearly 800 research projects at a breakneck pace, wiping out significant chunks of funding to entire scientific fields
Read the full story: https://go.nature.com/3EuFRPV
Read the full story: https://go.nature.com/3EuFRPV
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
For patients with IgG4-related disease, there are no approved therapies. Research findings on the efficacy and safety of inebilizumab ― a monoclonal antibody that targets and depletes CD19+ B-cells ― are summarized in a new Quick Take video. nej.md/421enZX
#MedSky #RheumSky
#MedSky #RheumSky
Inebilizumab for IgG4-Related Disease | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Inebilizumab for IgG4-Related Disease
nej.md
March 30, 2025 at 1:09 PM
For patients with IgG4-related disease, there are no approved therapies. Research findings on the efficacy and safety of inebilizumab ― a monoclonal antibody that targets and depletes CD19+ B-cells ― are summarized in a new Quick Take video. nej.md/421enZX
#MedSky #RheumSky
#MedSky #RheumSky
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
🚨 New: Spleen-resident macrophages (MMMs) can directly activate CD8+ T cells to fight tumors – independently of dendritic cells. They use a vacuolar MHC-I pathway & need Batf3 for this antitumor response.
🧠 A game-changer for immunotherapy?
🔗 www.cell.com/immunity/abs... @cp-immunity.bsky.social
🧠 A game-changer for immunotherapy?
🔗 www.cell.com/immunity/abs... @cp-immunity.bsky.social
March 26, 2025 at 10:12 AM
🚨 New: Spleen-resident macrophages (MMMs) can directly activate CD8+ T cells to fight tumors – independently of dendritic cells. They use a vacuolar MHC-I pathway & need Batf3 for this antitumor response.
🧠 A game-changer for immunotherapy?
🔗 www.cell.com/immunity/abs... @cp-immunity.bsky.social
🧠 A game-changer for immunotherapy?
🔗 www.cell.com/immunity/abs... @cp-immunity.bsky.social
Or upfront ablation, when appropriate... ;)
💫HPB Journal Highlight 💫 📢 New AHPBA Guidelines! For colorectal liver metastases: MRI is preferred, PET for extra-hepatic disease, and upfront surgery over chemo for resectable cases. Surgeons play a key role! 🔬 🔗https://tinyurl.com/yknj83jj
#ColorectalCancer #LiverMetastases
#ColorectalCancer #LiverMetastases
March 26, 2025 at 12:49 PM
Or upfront ablation, when appropriate... ;)
Terrible indeed!
Everyone should be supporting and advocating for MORE (not less) funding for research on such devastating diseases as Pancreatic Cancer, especially when their incidence is rising!...
@pancan.bsky.social @pancreaticcanuk.bsky.social @pce-europe.bsky.social @letswinpc.bsky.social
Everyone should be supporting and advocating for MORE (not less) funding for research on such devastating diseases as Pancreatic Cancer, especially when their incidence is rising!...
@pancan.bsky.social @pancreaticcanuk.bsky.social @pce-europe.bsky.social @letswinpc.bsky.social
This is absolutely devastating.
My young lab has benefitted from a DOD Pancreatic Cancer Research Program Idea Development Award that allowed me to extend my research program in exciting new directions that wouldn't have happened without this critical support.
Just terrible....
My young lab has benefitted from a DOD Pancreatic Cancer Research Program Idea Development Award that allowed me to extend my research program in exciting new directions that wouldn't have happened without this critical support.
Just terrible....
March 26, 2025 at 12:40 PM
Terrible indeed!
Everyone should be supporting and advocating for MORE (not less) funding for research on such devastating diseases as Pancreatic Cancer, especially when their incidence is rising!...
@pancan.bsky.social @pancreaticcanuk.bsky.social @pce-europe.bsky.social @letswinpc.bsky.social
Everyone should be supporting and advocating for MORE (not less) funding for research on such devastating diseases as Pancreatic Cancer, especially when their incidence is rising!...
@pancan.bsky.social @pancreaticcanuk.bsky.social @pce-europe.bsky.social @letswinpc.bsky.social
Couldn't agree more with this. Precision dosing is the way. Max tolerated dose treatment by default, can detrimental for some patients, especially those that rely to a bigger extent on immune-mediated tumor control, and whose immune system is crippled by MTD chemo.
🚨 Precision Dosing IS Precision Oncology 🧬💡
An editorial in Annals of Oncology by Dr. @viveksubbiah.bsky.social reframes precision oncology, arguing that “precision dosing is precision oncology.” 👇
#Onco404 #Oncology #Cancer #PrecisionOncology #CancerResearch #PersonalizedMedicine
An editorial in Annals of Oncology by Dr. @viveksubbiah.bsky.social reframes precision oncology, arguing that “precision dosing is precision oncology.” 👇
#Onco404 #Oncology #Cancer #PrecisionOncology #CancerResearch #PersonalizedMedicine
March 23, 2025 at 4:28 PM
Couldn't agree more with this. Precision dosing is the way. Max tolerated dose treatment by default, can detrimental for some patients, especially those that rely to a bigger extent on immune-mediated tumor control, and whose immune system is crippled by MTD chemo.
Kicking off an exciting Clinical Cancer Genomics 2025 conference with an overview of national molecular profiling strategies of 6 EU countries. Important points:
-WGS provides prognostic info (not just actionable targets)!
-Need to more data on various ancestries
-Need to increase testing!
#CCG2025
-WGS provides prognostic info (not just actionable targets)!
-Need to more data on various ancestries
-Need to increase testing!
#CCG2025
March 20, 2025 at 9:42 AM
Kicking off an exciting Clinical Cancer Genomics 2025 conference with an overview of national molecular profiling strategies of 6 EU countries. Important points:
-WGS provides prognostic info (not just actionable targets)!
-Need to more data on various ancestries
-Need to increase testing!
#CCG2025
-WGS provides prognostic info (not just actionable targets)!
-Need to more data on various ancestries
-Need to increase testing!
#CCG2025
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
Learn more about the APAChE study:
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
March 18, 2025 at 7:30 PM
Learn more about the APAChE study:
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
📄 Read the full results published in NEJM: nej.md/3IrM6T8
📄 Read the editorial by Philip J. Landrigan, MD: nej.md/48CvGSs
📺 Watch the interview with Dr. Landrigan: nej.md/41SCs6f
Nice summary video by @nejm.org on the INSEMA trial
👉In T1/small T2 breast cancers with clinically negative axilla, omitting SLN Biopsy is non-inferior to performing it:
✅ est. 5y inv.DFS of 92% at 6 years median f/up
✅ signif. less lymphedema & arm pain/restriction
www.nejm.org/do/10.1056/N...
👉In T1/small T2 breast cancers with clinically negative axilla, omitting SLN Biopsy is non-inferior to performing it:
✅ est. 5y inv.DFS of 92% at 6 years median f/up
✅ signif. less lymphedema & arm pain/restriction
www.nejm.org/do/10.1056/N...
Omitting Sentinel-Node Biopsy in Small Breast Cancers | NEJM
Quick Take Video Summary from The New England Journal of Medicine — Omitting Sentinel-Node Biopsy in Small Breast Cancers
www.nejm.org
March 15, 2025 at 5:45 PM
Nice summary video by @nejm.org on the INSEMA trial
👉In T1/small T2 breast cancers with clinically negative axilla, omitting SLN Biopsy is non-inferior to performing it:
✅ est. 5y inv.DFS of 92% at 6 years median f/up
✅ signif. less lymphedema & arm pain/restriction
www.nejm.org/do/10.1056/N...
👉In T1/small T2 breast cancers with clinically negative axilla, omitting SLN Biopsy is non-inferior to performing it:
✅ est. 5y inv.DFS of 92% at 6 years median f/up
✅ signif. less lymphedema & arm pain/restriction
www.nejm.org/do/10.1056/N...
👇 Not promising at all... 😣
Chemical industry lobbyists will run chemical safety oversight at US EPA - The Lancet Oncology www.thelancet.com/journals/lan...
Chemical industry lobbyists will run chemical safety oversight at US EPA - The Lancet Oncology www.thelancet.com/journals/lan...
Chemical industry lobbyists will run chemical safety oversight at US EPA
The Trump administration is putting lobbyists and attorneys from the petroleum and
chemical industries into leadership positions at the US Environmental Protection Agency
(EPA). Several of these indiv...
www.thelancet.com
March 10, 2025 at 12:22 PM
👇 Not promising at all... 😣
Chemical industry lobbyists will run chemical safety oversight at US EPA - The Lancet Oncology www.thelancet.com/journals/lan...
Chemical industry lobbyists will run chemical safety oversight at US EPA - The Lancet Oncology www.thelancet.com/journals/lan...
This is consistent with our 2021 @annsurgoncology.bsky.social paper on resectable PDAC showing better OS after metachronous Extrahepatic-only recurrence, vs Liver recur: link.springer.com/article/10.1...
👉 PDAC #organotropism informs on tumor biologic aggressiveness. @metastasisresearch.bsky.social
👉 PDAC #organotropism informs on tumor biologic aggressiveness. @metastasisresearch.bsky.social
March 1, 2025 at 10:30 PM
This is consistent with our 2021 @annsurgoncology.bsky.social paper on resectable PDAC showing better OS after metachronous Extrahepatic-only recurrence, vs Liver recur: link.springer.com/article/10.1...
👉 PDAC #organotropism informs on tumor biologic aggressiveness. @metastasisresearch.bsky.social
👉 PDAC #organotropism informs on tumor biologic aggressiveness. @metastasisresearch.bsky.social
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
Miriam Merad & Co @sinaiimmuno.bsky.social
outline the molecular basis of #DendriticCell maturation and the mechanisms through which cancer impairs #DC maturation and consider the potential for DC-focused cancer #immunotherapeutics.
📖 ⬇️
outline the molecular basis of #DendriticCell maturation and the mechanisms through which cancer impairs #DC maturation and consider the potential for DC-focused cancer #immunotherapeutics.
📖 ⬇️
#REVIEW 🚨
bit.ly
February 12, 2025 at 5:23 PM
Miriam Merad & Co @sinaiimmuno.bsky.social
outline the molecular basis of #DendriticCell maturation and the mechanisms through which cancer impairs #DC maturation and consider the potential for DC-focused cancer #immunotherapeutics.
📖 ⬇️
outline the molecular basis of #DendriticCell maturation and the mechanisms through which cancer impairs #DC maturation and consider the potential for DC-focused cancer #immunotherapeutics.
📖 ⬇️
Reposted by Constantinos Zambirinis, MD, MRes, FSSO
In case you missed our live event covering the latest in #pancreaticcancer clinical trials, you can watch the full recording now at pancan.org/clinicaltrials2025 🔬💜 Learn from experts about the basics of clinical trials, what developments are on the horizon and how to find the right trial for you.
Clinical Trials: At the Leading Edge of Progress
Join PanCAN on Jan. 30, at 11 a.m. PT / 2 p.m. ET, for an educational discussion about pancreatic cancer clinical trials and new developments in the field. RSVP for the event here:…
pancan.org
February 1, 2025 at 12:25 AM
In case you missed our live event covering the latest in #pancreaticcancer clinical trials, you can watch the full recording now at pancan.org/clinicaltrials2025 🔬💜 Learn from experts about the basics of clinical trials, what developments are on the horizon and how to find the right trial for you.
Amazing story! www.kathimerini.gr/society/5634...
«Νιώθω την αγωνία, το “χνώτο” του θανάτου»
Σε ηλικία 14 ετών έδωσε μάχη με επιθετικό σάρκωμα. Σήμερα είναι τελειόφοιτη Ιατρικής, με καθηγητή τον χειρουργό της.
www.kathimerini.gr
January 30, 2025 at 11:38 AM
Amazing story! www.kathimerini.gr/society/5634...
Ok let's see what this platform has to offer, given X's decline... :)
January 29, 2025 at 4:46 PM
Ok let's see what this platform has to offer, given X's decline... :)